Roughly 50 million people live with epilepsy, yet more than half of those with suspected genetic causes never receive a clear diagnosis. Researchers at the Duncan Neurological Research Institute at Baylor College of Medicine have identified a potential explanation for this diagnostic gap. Their findings suggest that epilepsy often stems from a combination of two defective genes rather than a single mutation.
By studying fruit flies, the team discovered the actin-mitochondria-glutamate, or AMG, pathway. This chain begins with defective actin, which forms the cell's internal scaffolding. When this scaffolding is flawed, it leads to excessive mitochondrial fission and a buildup of harmful reactive oxygen species. This process eventually causes neurons to release too much glutamate, triggering seizures.
The study suggests that current genetic testing, which often focuses on finding one severe gene defect, might miss the impact of two combined, less-severe mutations. By looking for specific variant pairs within the AMG pathway, scientists believe they could provide answers to families who previously received uninformative test results.
While the research identified two compounds that reduced seizures in fruit flies, these are not approved treatments for human use. The study serves as a starting point for potential drug development rather than an immediate change to clinical care. For patients and families, the most immediate impact is the potential for better diagnostic clarity. Anyone with questions regarding their specific diagnosis should consult a neurologist to discuss the implications of genetic testing.